Hatch/Waxman Reinterpretation Underpins Change In 30-Month Stay Policy
This article was originally published in The Tan Sheet
Executive Summary
FDA's proposal to allow only one 30-month stay of approval for ANDAs hinges on a reinterpretation of Hatch/Waxman language declaring that patent holders must be notified if a generic application is amended to "include" a Paragraph IV certification
You may also be interested in...
Senate Health Committee Plans To Codify FDA Generic Drug Proposal
The Senate Health & Education Committee plans to codify FDA's Hatch/Waxman reform proposal after the final rule is issued
Senate Health Committee Plans To Codify FDA Generic Drug Proposal
The Senate Health & Education Committee plans to codify FDA's Hatch/Waxman reform proposal after the final rule is issued
Senate Health Committee Plans To Codify FDA Generic Drug Proposal
The Senate Health & Education Committee plans to codify FDA's Hatch/Waxman reform proposal after the final rule is issued